Last edition
News about Safety
COVID medicines medical devices: parliamentary panel for framing price control regime
A Parliamentary panel has recommended framing a new price control regime specific for medicines and medical devices for COVID-19 management and put them under price control with no annual increase in prices allowed till the pandemic is entirely over in the country
Safety | 22/03/2022 | By Darshana | 629
A Synopsis Of Themis Medicare Viralex
Mumbai-based pharmaceutical company Themis Medicare?s anti-viral drug Viralex has received Drugs Controller General of India?s (DCGI) approval, the company informed the stock exchange on Monday
Safety | 21/03/2022 | By Darshana | 589
Second R&D Center Of Boston Scientific Corporation Inaugurated In Pune
The second Research and Development Center is launched by the Boston Scientific Corporation in Pune. The major goal of this move is to make capital out of India?s expertise in R&D and to provide manifold opportunities for engineers and front-runners in the country
Safety | 16/03/2022 | By Darshana | 1103
First reference lab in Kolkata launched by Lupin
The new Reference Laboratory at Kolkata has capabilities to conduct a broad spectrum of routine and specialized tests in the fields of molecular diagnostics, cytogenetics, flow cytometry, histopathology, cytology, microbiology, serology, haematology, immunology and routine biochemistry
Safety | 11/03/2022 | By Darshana | 818
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of Intas Pharmaceuticals immunising agent immunoglobulin combination at 15 per cent higher than the existing human normal immunoglobulin solution for infusion 5%, since it is an incremental innovation having advantage without any increased side effect
Safety | 08/03/2022 | By Darshana | 710
US FDA approval: CTI BioPharma's bone marrow cancer drug
The drug, Vonjo (pacritinib), belongs to a class of anti-inflammatory treatments called JAK inhibitors, and will compete with Incyte Corp?s Jakafi and Bristol Myers? Inrebic, which were approved in 2011 and 2019 respectively for treating Myelofibrosis
Safety | 04/03/2022 | By Darshana | 784
The decision comes as the latest in the drug regulator?s efforts to classify the medical devices sold in the country based on the perceived risk of the product type and its use in patients. The measure is to help the authority to bring in all the medical devices under the regulatory control, according to experts
Safety | 28/02/2022 | By Darshana | 692
Stempeutics gets DCGI nod for phase-III clinical trial on its product for treating COVID patients
Stempeutics yesterday said it has received DCGI clearance to conduct phase-III clinical trial on its product for treating COVID-19 patients suffering from Acute Respiratory Distress Syndrome (ARDS). The company will be using its stem cell product, Stempeucel, for conducting the label extension phase-III clinical trial
Safety | 20/01/2022 | By Darshana | 499
DGFT imposes restriction on export of anticoagulant enoxaparin & intra-venous immunoglobulin
Amid the rising cases of Covid-19 and Omicron variant in the country, the Directorate General of Foreign Trade (DGFT) has imposed restriction on export of anticoagulant enoxaparin and intravenous immunoglobulin (IVIG) active pharmaceutical ingredients and their formulations to ensure their adequate supply in the domestic market
Safety | 11/01/2022 | By Darshana | 565
Dr Reddy's Labs gets DCGI nod to launch molnupiravir in India
Dr. Reddy's Laboratories Ltd announced that it has received Emergency Use Authorization from the Drugs Controller General of India (DCGI) to manufacture and market the oral anti-viral drug molnupiravir capsules 200 mg for the treatment of adult patients with Covid-19, with SpO2 >93% and who have high risk of progression of the disease including hospital
Safety | 29/12/2021 | By Darshana | 510
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy